A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT01192971
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    apatinib p.o. once daily for 4 weeks

Study Details

This phase II trial will be studying how well Apatinib working in patients with Hepatocellular carcinoma.

Key Dates

Start date
Jun 30, 2010
Status verified
Feb 2023
Primary completion
Jul 31, 2013
Completion
Jul 31, 2013

Study Design

Enrollment
121 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A: 850mg
    A: Experimental apatinib 850 mg qd p.o, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
  • Experimental: B: 750mg
    B: Apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Primary Outcome Measure

TTP (Time to Progression) [ Time Frame: 8 weeks ]

Related Studies